:1425-34 (April 10) Study Type: POEM Purpose: Does long-term, low-intensity warfarin therapy reduce the risk of recurrence of venous thromboembolism in patients who have had a previous idiopathic venous thrombosis? Also, would those with factor V Leiden or prothrombin polymorphism benefit from this therapy? Study Duration: 3 years, 2.1 median follow-up Trial Design: 28-day open-label run-in phase to ensure that all patients could achieve an INR of 1.5-2 without exceeding the dose of warfarin 10 mg, also patient were excluded if compliance was < 85%. Randomized, double-blinded, multicenter, warfarin vs matching placebo with blinded evaluation of the INR by a central committee, sham dose adjustments of placebo were made to ensure blinding Patients: 508 patients; 53 yrs; 47% female; 87% white; 10% black; BMI = 29.9, ~8% had history of diabetes, ~40% had > 2 previous thromboembolic events, median 6 month duration of full-dose warfarin therapy, ~2 month time between cessation of full-dose warfarin and enrollment. No statistical difference between patients in both groups. Inclusion: men and women, 30 yrs and up, documented idiopathic (those not occurring within 90 days after surgery or trauma) venous thromboembolism, they had to have completed at least 3 months of full-dose warfarin Exclusion: history of metastatic cancer, major GI bleed, hemorrhagic stroke, life expectancy of < 3 yrs, those being treated with antiplatelets including aspirin at dose > 325 mg, lupus anticoagulant antibodies, antiphospholipid antibodies Outcome Events: See result section
1.
Are 
3.
Will the results help me? * Median INR = 1.7 in the warfarin group, with a warfarin dose of 4 mg (range = 0.5 -10 mg) * Of the total 51 events, 39 were DVT 's and 12 were PE's * Of the 8 deaths, 2 were due to fatal pulmonary embolism, one death due to fatal hemorrhagic stroke, all these were in the placebo grp. * the absence or presence of factor V Leiden or prothrombin polymorphism had no effect on outcome * no real difference in males vs female * no differences between groups stratified on age, number of previous events, time since randomization, time since cessation of full-dose warfarin therapy * There were 15 recurrent events in those patients discontinuing therapy before the trial (n = 120) -8 in the placebo grp, 7 in the warfarin grp
